
Fecal microbiota transplants have been used to treat various ailments, from obesity to irritable bowel syndrome, to mixed success. Rebyota is a blend of donor stool, saline, and laxative solution given in a single treatment as an enema. FDA granted approval for a feces-based microbial treatment for a C. difficile infection that can become life-threatening. In the US, C. Difficile infections are associated with up to 30,000 deaths per year. The FDA noted that given the variability of fecal matter, there is a potential that it could contain an infectious agent or food allergensens. The approval is an advance in advance of ‘an advance of advance in the advance of Rebyby . . .
Read more at arstechnica.com